Motivation: Circulating tumor cells (CTCs) are important in hematogenous cancer metastasis, and are usually studied by isolation from small peripheral blood samples. However, little is known about the shortterm dynamics of CTC in vivo.
Introduction
Circulating tumor cells (CTCs) are of great interest in cancer research due to their importance in hematogenous cancer metastasis. CTCs shed from tumors into the peripheral blood (PB), a small number of which may form metastases. It is these metastases that are extremely difficult to control clinically, and eventually result in 90% of cancer-related deaths [1, 2] . As such, CTCs are highly studied both clinically and in pre-clinical small animal models. The vast majority of these studies involve "liquid biopsy" techniques, wherein CTCs are isolated in fractionally small blood samples [3, 4] . While it has been clearly established that elevated CTCs in patient blood samples is associated with reduced overall survival for major cancers such as breast [5] , colorectal [6] , and prostate [7] , the clinical value of CTC enumeration (beyond detection) is still unclear [8] [9] [10] [11] . One major known challenge with liquid biopsy includes the heterogeneity of CTCs, leading to increased efforts for molecular and genetic characterization of individual CTCs after isolation [12] [13] [14] .
A less studied challenge is with respect to quantification accuracy: liquid biopsy implicitly assumes that the number of CTCs in small blood samples is representative of the whole peripheral blood volume (PBV). Several researchers have shown that this assumption may be dubious, due to the rarity of CTCs in the blood, the fractionally small volume of blood samples relative to the total PBV, and the expected statistical variability in detection events [15, 16] . The only FDA cleared method for enumerating CTCs clinically is currently CellSearch, which is used to analyze 7.5 mL blood samples, or about 0.015% of the approximately 5L human PBV [6, 17, 18] . Other experimental microfluidic platforms typically analyze similarly small blood volumes, usually in the range of 2-10 mL [19] [20] [21] . In pre-clinical mouse studies, blood collection is typically limited to 100-200 L of blood every two weeks, or about 5-10% of the approximately 2mL mouse PBV [22, 23] As such, if sufficiently rare, CTCs may not be detected, even if metastatic disease is present. For instance, Maestro et. al. found that only 62.3% of patients with metastasized epithelial cancers had at least 1 CTCs in 7.5mL samples over the detection limit [24] . Moreover, most theoretical treatments of the problem assume that CTC detection statistics should follow a Poisson distribution [15, 25] , which further assumes that CTCs are well mixed in the blood, and that the average number of CTCs in circulation does not change significantly over the short-term (minutes, hours or days surrounding the blood draw).
'In vivo flow cytometry' (IVFC) is a general term for optical instrumentation designed to enumerate circulating cells directly in vivo, most often by fluorescence or photoacoustic methods [23, 26] . We recently developed 'diffuse in vivo flow cytometry' (DiFC), which is a fluorescence-based, small animal research instrument specifically developed for enumerating extremely rare (less than 1 cell per mL) cells circulating in the peripheral blood (PB) [27] [28] [29] [30] . DIFC uses highly scattered light to sample large blood volumes in large veins and arteries. The main advantage of DiFC compared to microscopy-IVFC is therefore sensitivity, in that it samples at least an order of magnitude more circulating blood per unit time (50 L versus 1 L of blood per minute) [23] . We recently used DiFC to monitor CTC dissemination during disease development in mouse xenograft models of multiple myeloma (MM) and Lewis lung carcinoma (LLC) [30, 31] .
Until now, we used DiFC to measure only the time-averaged (mean) number of CTC in circulation on a given day, but did not consider the short-term dynamics of CTC detections which varied significantly on the timescale of seconds or minutes. These short-term variations are not observable by drawing blood samples (liquid biopsy), and are therefore uniquely measurable with in vivo methods such as DiFC. There is to our knowledge only one previous report studying CTC dynamic fluctuations over time in pre-clinical models with a fluorescence microscopy-based IVFC instrument [32] . In this paper, we studied CTC detection rates in time intervals of 24, 120, 240, and 480 seconds, which correspond to approximately 1, 5, 10, and 20% of the mouse PBV, respectively. We also compared these against in silico data and phantom models with well mixed fluorescent microspheres.
This analysis revealed some interesting observations with insights for the use of small blood samples for the study of CTCs. Overall, DiFC data revealed that CTC numbers are highly dynamic over short-time scales. These data provide direct in vivo confirmation of the notion that use of fractionally small blood samples for estimation of CTC burden is highly sensitive to sampling error, and is generally quantitatively inaccurate [15, 16, 25] . These data also showed that the variability of CTC detection rates often exceeded that predicted by Poisson statistics, suggesting that the CTCs are in general not well-mixed in the peripheral blood. As we discuss, this can be explained by non-constant tumor shedding dynamics, and the short half-life of CTCs in circulation [19, 33] .
Methods

DiFC Instrument and Signal Processing
The DiFC instrument and data processing algorithms were described in detail previously [29, 30] . Briefly, two specially designed fiber-optic probes are placed in-line along a major blood vessel (in this case, the ventral side of the tail of a mouse) as shown in figure 1a,b . Fluorescently-labeled CTCs are detected by laser induced fluorescence as they pass through the DiFC field of view ( fig. 1c) . Integrated filters and collection optics allowed minimization of the non-specific tissue autofluorescence, and detection of weak transient fluorescent peaks from moving cells. DiFC analysis also uses "peak matching" between the two detection fibers to identify cells moving the in the forward (arterial) or reverse (venous) directions ( fig. 1c ). As described in Tan 2019, peaks were matched based on their amplitude, temporal width (which is indicative of cell speed through fiber field of view), and temporal delay between channels (speed) [29] . This approach allows us to monitor the count rate in a single blood vessel (in this case the ventral caudal artery) over time, and almost complete elimination of false-positive detections due to e.g. motion artifacts, which do not meet the matching criteria [30] . DiFC detections of arterial CTCs can be visualized using a simplified temporal raster event plot: as shown in fig. 1f , each vertical black line represents a single detection of an arterial CTC in time.
Analysis of DiFC scan intervals and equivalent blood volumes:
As such, DiFC data therefore allowed us to observe and analyze the rate of CTC detections continuously over time. We previously calculated that DiFC samples approximately 50 L per minute [30] of circulating peripheral blood. Central to our analysis here is the assumption that CTC counts in a specific DiFC time interval is equivalent to the number of CTCs that would be counted in a blood sample of corresponding volume drawn at that time. For example, a 24 s DiFC scan interval is equivalent to approximately 20 L of blood, or about 1% of the PBV of a mouse. In this work, we considered 24, 120, 240 and 480 s DiFC scan intervals, equivalent to 20, 100, 200 and 400 L, or about 1%, 5%, 10% and 20% of the PBV. 
DiFC Data Sets
In this work, we analyzed four data sets as follows: i) Lewis lung carcinoma (LLC) lung metastasis model: We used DiFC to detect CTCs in circulation during LLC development in mice [31] . 10 6 LLC cells (LL/2.GFP.Luc) expressing the green fluorescent protein (GFP) were implanted sub-cutaneously in nude mice (N = 24) and allow to grow for up to 5 weeks after inoculation. DiFC was performed for 40-65 minutes 1-7 times over the course of tumor development.
CTCs were observed in circulation as early as 5 days after implantation and generally increased over time.
However, as discussed in Fitzgerald et. al. [31] , CTCs were exceedingly rare, with detection rates ranging ii) Multiple myeloma (MM) disseminated xenograft model: As described in Patil 2019, we also used DiFC to measure CTC dissemination in a MM xenograft model [30] . Briefly, 5 x 10 6 MM.GFP.Luc cells were injected intravenously in SCID mice. Each mouse was scanned with DiFC for 35 minutes, twice weekly up to 5 weeks following inoculation. We also regularly performed Bioluminescence Imaging (BLI) to track disease development. In contrast to the LLC model, MM CTC numbers generally increased over time, and were more abundant. Example DiFC data for one mouse is shown in figs. 2d-f, where an increase in GFP+ CTCs measured in circulation was observed alongside MM burden (BLI). Only data sets where the average count rate was at least 0.5 CTCs per minute were used, for a total of N = 18 data sets with rates ranging from 0.6 to 19.6 CTCs per minute, or about 12 to 392 CTCs per mL of mouse blood. 
iii) Microspheres in optical flow phantoms in vitro:
We also used an optical flow phantom model with suspensions of fluorescent microspheres that were well-mixed, as we have done previously [30] . The 
iv) Simulated DiFC data using Poisson statistics:
We also simulated Poisson-distributed sequences of DiFC detections in silico as follows. The time between CTC detections follow an exponential distribution given by [15, 25] :
Where λseconds = DiFC scan average number of cells per second. We generated 35-minute data sets,
where CTC detections were simulated in Matlab (The Mathworks Inc., Natick, MA) with an exponential random number generator with mean rates of detection (λseconds) equal to those of the MM and microsphere data sets, input 3 times each (N = 108 simulated scans).
Likewise, based on Poisson statistics, the probability of finding k CTCs in a blood sample, or the equivalent time interval of DiFC data, is expected to follow the distribution:
Where, λT is the mean number of cells per blood sample (time interval). Note that = where T is the length of the respective time interval in seconds.
Results
Use of small equivalent blood samples frequently result in missed CTCs
We previously reported measurement of CTC numbers in blood in an LLC metastatic xenograft model [31] .
We showed that while CTC count rate approximately correlated with the size of the primary tumor, significant day-to-day variability was observed and CTC numbers did not in general increase monotonically over time. Further analysis of our 60-minute DiFC scans in these mice showed that while pulmonary metastases were eventually observed in all cases, the DiFC count rate, and hence the number of CTCs in circulation at any given time was very low. This count rate could be directly related to the number of CTCs Given these data, we consider the number of CTCs that would be detected in random 24s, 120s, . 3c) , a 24s interval would yield zero CTC detections 89% of the time (fig.   3f ). As might be expected, this probability was improved significantly for larger equivalent blood samples and for higher numbers of CTCs. For example, for a CTC burden of 10 CTCs per mL and an equivalent 20% PBV sample ( fig. 3o) , at least 1 CTC was detected 99% of the time.
The fraction of time intervals (equivalent blood samples) where at least 1 CTC was counted for all LLC mouse studies are shown in figure 4 . In combination these data underscore the fact that analysis of fractionally small (1-5% PBV) blood samples frequently resulted in detection of no CTCs, even when metastatic disease was present. Use of larger intervals significantly increased the likelihood of detection of at least 1 CTC. Hence these data provide direct animal model validation of the notion that 'more is better'
for enumeration and analysis of CTCs [16] . 
Estimating CTC numbers from small blood samples is quantitively inaccurate
We were also interested in the quantitative accuracy of CTC count from a fractionally small blood sample.
To study this, we used data from our previously reported MM.1s disseminated mouse xenograft model,
where CTCs were significantly more abundant [30] . Example data is shown in figure 5a , which shows a We also compared these distributions to Poisson statistics which, as noted, are frequently assumed for CTC distributions in blood [15, 25, 34] . Specifically, we calculated the probability of k cells (equation 2) in an equivalent blood sample given the scan mean for each interval size (figs. 5f-i, dashed lines). By inspection, it can be seen that the DiFC-measured distribution of detection rates did not appear to follow the Poisson distributions, particularly for larger samples. The implications of this are discussed in more detail in section 3.3 below.
To better quantify the variability we observed, we also computed the deviation from the scan mean (DFSM) of the number of CTCs in each ith equivalent sample (Ci) as:
where λT is the mean number of CTC detections over the full scan for each sample size.
We then considered the fraction of scan intervals (equivalent blood samples) where the DFSM was equal to or less than 25% and 50%. We did this for all 18 data sets we analyzed, as summarized in figure   6 . Use of 25% and 50% DFSM ranges are somewhat arbitrary, but are illustrative of sufficiently large error to affect decision makingfor example in determining whether a sample has 4 or 5 CTCs (breast and prostate cancer) or 2 or 3 CTCs (colorectal cancer) [6, 17] .
Taken together, these data show that quantitative estimation of CTC numbers from a single sample is extremely challenging. For example, for a scan interval of 120 s (5% PBV), the median probability of randomly obtaining a CTC count within 25% of the scan mean was only 40.8% ( fig. 6a) . Likewise, the probability of obtaining a CTC count within 50% of the mean was 72.3% ( fig. 6b) . Unsurprisingly, all else being equal, use of larger blood sample volumes yielded higher probability of obtaining accurate count than smaller samples [16] . 
The variability in CTC detection rate was often higher than predicted by Poisson statistics
Because CTC detection is a random process, some variability of the measurements is naturally expected.
However, the variability observed in the MM DXM data sets (for example in figure 5 ) often appeared to exceed that predicted by Poisson statistics. As a simple illustration of this, we plotted the standard deviation of CTC counts against the square root of the mean (T). This was repeated for 24, 120, 240 and 480 s intervals, for all 18 data sets. The results are shown in figs 7a-d. As shown, the measured standard deviation was frequently higher than √ .
To verify that this effect was not an artifact of the DiFC measurement or our data analysis approach, we repeated this analysis for simulated DiFC data where detections were Poisson distributed (equation 1)
as shown in figs 7e-h. We also performed DiFC measurements in a tissue-simulating optical flow phantom with suspensions of fluorescent microspheres that were well-mixed in solution as shown in figs. 7i-l. In both cases, the standard deviation more closely agrees with the square root of the scan mean, as would be expected.
Based on this analysis, we next developed a test for whether the variability in CTC detection rates exceeded that predicted by Poisson statistics. For each data set, we calculated the fraction of observed time intervals with a number of CTCs within X% DFSM was calculated for X from 1% to 100% as shown in figs. 7m, n. The equivalent curves predicted from Poisson statistics were also calculated as indicated by dotted lines in the plots. These were compared to the experimental measurements for 5%, 10%, and 20%
PBV intervals at the 25% and 50% DFSM points and the sum of calculations from 1% to 100% DFSM (area under the curves in figs. 7m, n) . If the Poisson predictions were at least 15% larger than the experimental observations in a majority of these 9 comparisons, the data set was identified as "exceeds Poisson variability," otherwise it was identified as "consistent with Poisson."
Data sets meeting the definition of exceeding Poisson variability are plotted with red square markers in fig. 7 , whereas data sets that were consistent with Poisson statistics are plotted with blue markers.
As shown, by this definition, 8 of 18 (44%) of MM xenograft data sets had variability exceeding Poisson statistics. On the other hand, only 1 of 108 (0.9%) of the simulated data sets and 1 of 18 (6%) of the phantom microsphere data sets by chance had exceeded Poisson variability. The main practical implication of the result is that the likelihood of obtaining a quantitatively accurate CTC count from a single blood sample is actually worse than would be predicted by Poisson statistics for many of the in vivo data sets. Figure 7 . Comparison between the √ and the observed standard deviations: in vivo MM (a-d), simulations (e-h), and microspheres (i-l). Dotted lines show the 1:1 relationship that would be predicted from Poisson Statistics. Blue circles and red squares indicate data sets that are consistent with Poisson statistics and those that have greater variability than Poisson statistics, respectively. The fraction of observed time intervals with a number of CTCs within X% deviation from the scan mean was calculated from 1% to 100% for each data set. From these calculations, data sets were identified as either being consistent with Poisson or exceeding Poisson variability. Example MM DXM data sets for both cases are shown in (m) and (n), respectively.
Quantification of CTCs can be improved by averaging multiple samples
These data show that the mean number of detected CTCs varies significantly over the timescale of minutes, which further suggests that CTCs are not well-mixed in the peripheral blood. Likely physical explanations for this are discussed in more detail below. However, we hypothesized that based on this, averaging multiple small equivalent blood samples taken over the course of the scan should yield more accurate estimates of the true CTC count compared to a larger contiguous equivalent blood sample. For example, we compared five averaged 1% PBV measurements to a single 5% PBV measurement. For the former, we randomly sampled 3.96 million sets of five, 1% PBV samples from each MM DXM mouse data set.
The paired-difference (five 1% -5%) in probability of obtaining a measurement with DFSM less than or equal to 25% and 50% are shown in figure 8 . While the median improvement in the two groups is 7.5% and 5.2%, respectively, in individual cases the improvement was as high as 32.6%. Moreover, when the data sets were separated into those that had variability exceeding Poisson statistics, the median improvements rose to 20.8% and 18.3%, respectively. As would be expected, for data sets where the variability was consistent with Poisson statistics, there was essentially no paired improvement (2.0% and -0.09%, respectively). These results suggest that, in addition to sampling more blood volume, improved accuracy in CTC enumeration (at least in our animal xenograft model) can be obtained by averaging several samples taken over longer periods of time. 
Discussion
Although CTCs are widely studied using liquid biopsy methods, their use of infrequent, fractionally small peripheral blood samples means that they are blind to natural temporal fluctuations in CTC numbers that occur over the timescale of minutes or hours. In contrast, in vivo methods of cell enumeration like DiFC uniquely allow measurement of these CTC dynamics. As we have noted, DiFC is unique amongst fluorescence-IVFC methods in that it allows enumeration of particularly rare cell populations. DiFC data also suggests that CTCs may not be 'well-mixed' in the blood, meaning that the mean number of CTCs changes over time. It is well known that once shed into circulation, CTCs clear rapidly with a half-life of minutes or hours [19, 33, 35] . Previous DiFC and IVFC data are consistent with this [28, [36] [37] [38] [39] [40] . It has also been known for decades that tumors disseminate CTCs continuously at a rate of about 10 6 cells per gram of tumor tissue per day [41] . We were unable to find any specific published research on the short-term kinetics of CTC shedding into circulation, however it is possible or even likely that the rate of CTC shedding is not constant over the scale of minutes. For example, it has been shown that tumors cycle through hypoxia states on similar timescales [42] . The combination of short CTC half-life and nonconstant CTC shedding from the tumor implies that CTCs are both being shed into and being cleared from circulation over short time scales, which would account for the short-term higher-than-anticipated variation in CTC numbers. CTC numbers may be better described using a 'bursty' kinetic model, analogous to burstiness in RNA transcription [43] . In one LLC data set analyzed in this paper, for example, only a single detection was observed in a 60-minute DiFC scan (e.g. fig. 3a ), suggesting that the CTC cleared from circulation before it could be detected a second time (which would have been likely given that DiFC would have sampled several mL of blood). We also performed DiFC in a LLC model for even longer periods (4 hours), as shown in figure 9 , showing patterns of relatively high and low CTC activity. In practice, these data are consistent with the idea that improved CTC enumeration can be achieved by analysis of larger blood samples [15, 16] , either by liquid biopsy or by using in vivo methods such as IVFC [44] or implantable CTC capture devices [45] . Moreover, our data suggest that in cases where the mean number of CTCs changes over time, averaging of multiple blood samples should yield better quantitative estimation of CTC numbers than a single larger blood sample. The high-degree of CTC turnover in peripheral blood also suggests that anti-CTC therapeutic strategies such as so-called "CTC dialysis" [46, 47] are unlikely to succeed unless performed continuously.
Last, we acknowledge that these observations are made from two mouse models of cancer with immortalized cell lines. Whether these observations extend to other mouse models, or to human cancers is not yet known. However, these data are generally consistent with the small number of previous IVFC studies of short-term CTC numbers in mice [32] . "Spaghetti plots" of CTC numbers taken over time in human patients also suggest significant variation [48] . It is plausible that human cancers behave even more heterogeneously than mouse xenograft models. Extension of this work to other animal models of metastasis, and better modeling of CTC kinetics is the subject of ongoing research in our group.
